$TLCC
Twinlab Consolidated Holdings Inc

2021 Q4 Form 10-K Financial Statement

#000175392622000353 Filed on March 29, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $16.25M $72.09M $19.34M
YoY Change -15.97% 8.65% 21.6%
Cost Of Revenue $17.67M $55.51M $20.15M
YoY Change -12.31% 0.07% 43.42%
Gross Profit -$1.419M $16.58M -$811.0K
YoY Change 74.97% 52.39% -143.74%
Gross Profit Margin -8.73% 23.0% -4.19%
Selling, General & Admin $1.547M $13.15M $2.676M
YoY Change -42.19% -19.25% -62.83%
% of Gross Profit 79.33%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $106.0K $80.00K $277.0K
YoY Change -61.73% 196.3% -27.68%
% of Gross Profit 0.48%
Operating Expenses $1.547M $13.15M $2.676M
YoY Change -42.19% -19.25% -62.83%
Operating Profit -$2.966M -$7.692M -$3.487M
YoY Change -14.94% 42.23% -34.77%
Interest Expense -$1.992M $8.611M -$2.465M
YoY Change -19.19% -3.83% -366.2%
% of Operating Profit
Other Income/Expense, Net $872.0K $1.376M -$21.00K
YoY Change -4252.38% -115.39% -101.47%
Pretax Income -$15.20M -$14.93M -$5.973M
YoY Change 154.55% 4.01% -78.58%
Income Tax $13.00K $13.00K $38.00K
% Of Pretax Income
Net Earnings -$15.22M -$14.94M -$6.011M
YoY Change 153.15% 3.83% -78.5%
Net Earnings / Revenue -93.65% -20.72% -31.09%
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$58.73K -$0.06 -$23.36K
COMMON SHARES
Basic Shares Outstanding 259.1M shares 258.8M shares 258.1M
Diluted Shares Outstanding 258.8M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.631M $3.631M $424.0K
YoY Change 756.37% 756.37% 57.04%
Cash & Equivalents $3.631M $424.0K
Short-Term Investments
Other Short-Term Assets $1.045M $1.045M $2.195M
YoY Change -52.39% -52.39% -29.62%
Inventory $5.814M $5.814M $6.301M
Prepaid Expenses $2.195M
Receivables $6.881M $6.881M $8.425M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.37M $17.37M $17.35M
YoY Change 0.15% 0.15% 6.41%
LONG-TERM ASSETS
Property, Plant & Equipment $140.0K $5.620M $65.00K
YoY Change 115.38% 17.7% -9.72%
Goodwill $0.00 $8.818M
YoY Change -100.0% 0.0%
Intangibles $576.0K $3.253M
YoY Change -82.29% -25.44%
Long-Term Investments
YoY Change
Other Assets $1.301M $1.301M $760.0K
YoY Change 71.18% 71.18% -8.87%
Total Long-Term Assets $7.497M $7.497M $17.61M
YoY Change -57.42% -57.42% 24.98%
TOTAL ASSETS
Total Short-Term Assets $17.37M $17.37M $17.35M
Total Long-Term Assets $7.497M $7.497M $17.61M
Total Assets $24.87M $24.87M $34.95M
YoY Change -28.85% -28.85% 15.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.047M $6.047M $4.712M
YoY Change 28.33% 28.33% -25.36%
Accrued Expenses $31.15M $31.15M $26.54M
YoY Change 17.36% 17.36% 28.38%
Deferred Revenue $2.160M $3.934M
YoY Change -45.09% 84.96%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $97.41M $97.41M $96.85M
YoY Change 0.58% 0.58% 6.28%
Total Short-Term Liabilities $136.8M $136.8M $132.0M
YoY Change 3.58% 3.58% 11.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $476.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $5.197M $5.197M $4.592M
YoY Change 13.18% 13.18%
Total Long-Term Liabilities $5.197M $5.197M $5.068M
YoY Change 2.55% 2.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $136.8M $136.8M $132.0M
Total Long-Term Liabilities $5.197M $5.197M $5.068M
Total Liabilities $142.0M $142.0M $137.1M
YoY Change 3.54% 3.54% 16.04%
SHAREHOLDERS EQUITY
Retained Earnings -$348.2M -$333.3M
YoY Change 4.48% 4.51%
Common Stock $231.6M $231.6M
YoY Change 0.0% 59295.64%
Preferred Stock
YoY Change
Treasury Stock (at cost) $500.0K $500.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares 134.8M shares 134.8M shares
Shareholders Equity -$117.1M -$117.1M -$102.1M
YoY Change
Total Liabilities & Shareholders Equity $24.87M $24.87M $34.95M
YoY Change -28.85% -28.85% 15.02%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$15.22M -$14.94M -$6.011M
YoY Change 153.15% 3.83% -78.5%
Depreciation, Depletion And Amortization $106.0K $80.00K $277.0K
YoY Change -61.73% 196.3% -27.68%
Cash From Operating Activities $3.380M $2.650M -$662.0K
YoY Change -610.57% -152.27% -3.92%
INVESTING ACTIVITIES
Capital Expenditures -$8.000K $155.0K $0.00
YoY Change 675.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$8.000K -$155.0K $0.00
YoY Change 675.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.889M $712.0K 209.0K
YoY Change -1003.83% -86.42% -118.56%
NET CHANGE
Cash From Operating Activities 3.380M $2.650M -662.0K
Cash From Investing Activities -8.000K -155.0K 0.000
Cash From Financing Activities -1.889M $712.0K 209.0K
Net Change In Cash 1.483M $3.362M -453.0K
YoY Change -427.37% 2083.12% -75.04%
FREE CASH FLOW
Cash From Operating Activities $3.380M $2.650M -$662.0K
Capital Expenditures -$8.000K $155.0K $0.00
Free Cash Flow $3.388M $2.495M -$662.0K
YoY Change -611.78% -149.02% -3.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001590695
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
97408000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
141957000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4592000 USD
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Entity File Number
EntityFileNumber
000-55181
CY2021 dei Entity Registrant Name
EntityRegistrantName
Twinlab Consolidated Holdings, Inc.
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3951742
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
4800 T-Rex Avenue, Suite 225
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
CY2021 dei City Area Code
CityAreaCode
561
CY2021 dei Local Phone Number
LocalPhoneNumber
443-4301
CY2021 dei Security12g Title
Security12gTitle
Common Stock
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q2 dei Entity Public Float
EntityPublicFloat
8250771000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
259092833 shares
CY2021 dei Auditor Firm
AuditorFirmId
270
CY2021 dei Auditor Name
AuditorName
Tanner LLC
CY2021 dei Auditor Location
AuditorLocation
Lehi, Utah
CY2021Q4 us-gaap Cash
Cash
3631000 USD
CY2020Q4 us-gaap Cash
Cash
424000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6881000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8425000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
5814000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
6301000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1045000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2195000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
17371000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
17345000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
140000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5480000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4710000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
576000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3253000 USD
CY2021Q4 us-gaap Goodwill
Goodwill
0 USD
CY2020Q4 us-gaap Goodwill
Goodwill
8818000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1301000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
760000 USD
CY2021Q4 us-gaap Assets
Assets
24868000 USD
CY2020Q4 us-gaap Assets
Assets
34951000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6047000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4712000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1039000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
742000 USD
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5422000 USD
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9372000 USD
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
26844000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
20359000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
136760000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
132032000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5197000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
231249000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
231250000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
476000 USD
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5197000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5068000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
137100000 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
393898884 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
392864182 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
394000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
393000 USD
CY2021Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
30000 USD
CY2020Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
30000 USD
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
134806051 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
134806051 shares
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
500000 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
500000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-348202000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333262000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-117089000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-102149000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24868000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34951000 USD
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
72089000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
66349000 USD
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55511000 USD
CY2021 us-gaap Gross Profit
GrossProfit
16578000 USD
CY2020 us-gaap Gross Profit
GrossProfit
10879000 USD
CY2021 us-gaap Selling Expense
SellingExpense
3416000 USD
CY2020 us-gaap Selling Expense
SellingExpense
1688000 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9736000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14599000 USD
CY2021 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
11118000 USD
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-7692000 USD
CY2021 us-gaap Interest Expense
InterestExpense
8611000 USD
CY2020 us-gaap Interest Expense
InterestExpense
8954000 USD
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
35000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1376000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8943000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14927000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14351000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14940000 USD
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
258837701 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257345636 shares
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
258837701 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
259079879 shares
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-87760000 USD
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14389000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-102149000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-117089000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14940000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14389000 USD
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
457000 USD
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1137000 USD
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
890000 USD
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
797000 USD
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
718000 USD
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
952000 USD
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
-958000 USD
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
499000 USD
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-710000 USD
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-3784000 USD
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
35000 USD
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1344000 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-133000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2021 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
11118000 USD
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2253000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1701000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1445000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
231000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1150000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-924000 USD
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
543000 USD
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-74000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1336000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1601000 USD
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-892000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
155000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000 USD
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-812000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2537000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9698000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2650000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5070000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
712000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5244000 USD
CY2021 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
3207000 USD
CY2020 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
154000 USD
CY2020Q4 us-gaap Cash
Cash
424000 USD
CY2019Q4 us-gaap Cash
Cash
270000 USD
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1344000 USD
CY2020 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
6674000 USD
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
632000 USD
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
2310000 USD
CY2021 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0 USD
CY2021Q4 us-gaap Cash
Cash
3631000 USD
CY2020Q4 us-gaap Cash
Cash
424000 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1375000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
1032000 USD
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span>Note <span style="border-left: none; border-right: none;">1</span> </span>–<span style="font-weight: bold;"> Nature of Business</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span style="font-style: italic;">Organization</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">Twinlab Consolidated Holdings, Inc. (the “Company”, “Twinlab,” “we,” “our” and “us”) was incorporated on October 24, 2013 under the laws of the State of Nevada as Mirror Me, Inc. On August 7, 2014, we amended our articles of incorporation and changed our name to Twinlab Consolidated Holdings, Inc.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span style="font-style: italic;">Nature of Operations</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">We are an integrated marketer, distributor and retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores, mass market retailers, specialty store retailers, on-line retailers and websites. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">Our products include vitamins, minerals, specialty supplements and sports nutrition products sold under the Twinlab<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name, a market leader in the healthy aging and beauty from within categories sold under the Reserveage Nutrition and ResVitale® brand names; diet and energy products sold under the Metabolife<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name; and a full line of herbal teas sold under the Alvita<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name. To accommodate consumer preferences, our products come in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, sprays and powders. These products are sold primarily through health and natural food stores and on-line retailers, supermarkets, and mass-market retailers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">We also perform contract manufacturing services for private label products. Our contract manufacturing services business involves the manufacture of custom products to the specifications of a customer who requires finished product under the customer’s own brand name.  We do not market these private label products as our business is to sell the products to the customer, who then markets and sells the products to retailers or end consumers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span style="font-style: italic;">Going Concern</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span>The accompanying consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. In most periods since our formation, we have generated losses from operations. At December 31, 2021, we had an accumulated <span>defic<span>i<span>t of</span></span> $</span>348,202<span>. H</span>istorical losses are primarily attributable to lower than planned sales resulting from low fill rates on demand due to limitations of our working capital, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with our debt refinancing, and impairment of our goodwill and intangible assets. Losses have been funded primarily through issuance of common stock and third-party or related party debt.</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span>Additionally, the Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact its customers and business partners. While the Company did not incur significant disruptions during the year ended December 31, 2021 from the COVID-19 pandemic, it is unable to predict the impact that the COVID-19 pandemic will have on its financial condition, results of operations and cash flows due to numerous uncertainties.</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span>Because of our history of operating losses and significant interest expense on our debt, we have a working capital deficiency of $119,389 at December 31, 2021.</span> <span> We also have $97,408 of debt, net of discount, presented in current liabilities. These continuing conditions, among others, raise substantial doubt about our ability to continue as a going concern.</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">Management has addressed operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; reducing manufacturing and operating costs and continuing to negotiate lower prices from major suppliers.  We believe that we will need additional capital to execute our business plan. If additional funding is required, there can be no assurance that sources of funding will be available when needed on acceptable terms or at all.</span></p>
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-348202000 USD
CY2021Q4 tlcc Working Capital Deficiency
WorkingCapitalDeficiency
-119389000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
97408000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span style="font-style: italic;">Use of Estimates</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant management estimates include those with respect to returns and allowances, allowance for doubtful accounts, reserves for inventory obsolescence, the recoverability of long-lived assets, intangibles and goodwill.</span></p>
CY2021Q4 tlcc Contract With Customer Deposit Liability Current
ContractWithCustomerDepositLiabilityCurrent
2104000 USD
CY2020Q4 tlcc Contract With Customer Deposit Liability Current
ContractWithCustomerDepositLiabilityCurrent
3874000 USD
CY2021Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
56000 USD
CY2020Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
60000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2160000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3934000 USD
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
72089000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
66349000 USD
CY2021Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
1391000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
511000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1127000 USD
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
120000 USD
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-14940000 USD
CY2021 us-gaap Dilutive Securities
DilutiveSecurities
0 USD
CY2020 us-gaap Dilutive Securities
DilutiveSecurities
-35000 USD
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14940000 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14424000 USD
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
257345636 shares
CY2021 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2020 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1734243 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
258837701 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
259079879 shares
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span style="font-style: italic;">Significant Concentration of Credit Risk</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;">The Company maintains its cash in bank deposit accounts which, at times, exceed federally insured limits. To date, the Company has not experienced a loss or lack of access to its invested cash; however, no assurance can be provided that access to the Company's invested cash will not be impacted by adverse conditions in the financial markets.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span>Sales to our top three customers aggregated to approximately 26% and 25% of total consolidated sales in 2021 and 2020, respectively. Sales to one of those customers were approximately 11% and 10% of total sales in 2021 and 2020, respectively. Accounts receivable from these customers were approximately 22% and 23% of total accounts receivable as of December 31, 2021 and 2020, respectively. </span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt;"><span>Our two major vendors accounted for 46% and 45% of purchases for the year ended December 31, 2021 and 2020, respectively. A third vendor represented an additional 11% and 12% of purchases for the year ended December 31, 2021 and 2020, respectively.</span></span></p>
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2016000 USD
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2053000 USD
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4586000 USD
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5994000 USD
CY2021Q4 us-gaap Inventory Gross
InventoryGross
6602000 USD
CY2020Q4 us-gaap Inventory Gross
InventoryGross
8047000 USD
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
788000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1746000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
6301000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
212000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
144000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
72000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
79000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
140000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000 USD
CY2021 us-gaap Depreciation
Depreciation
80000 USD
CY2020 us-gaap Depreciation
Depreciation
27000 USD
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
120000 USD
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
120000 USD
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
11222000 USD
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
13522000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10646000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10269000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
576000 USD
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3253000 USD
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
377000 USD
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1110000 USD
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2300000 USD
CY2020 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
116000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
116000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
116000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
108000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
0 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
456000 USD
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
97408000 USD
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
97323000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
97408000 USD
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
96847000 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
476000 USD
CY2016Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2500000 USD
CY2016Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.085 pure
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
11811649 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.14
CY2020 tlcc Class Of Warrant Or Right Granted During Period Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2020 tlcc Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2020 tlcc Class Of Warrant Or Right Canceled During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCanceledDuringPeriodExercisePriceOfWarrantsOrRights
0.37
CY2020 tlcc Class Of Warrant Or Right Exercised During Period Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights
1379601 shares
CY2020 tlcc Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6034702 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.07
CY2021 tlcc Class Of Warrant Or Right Granted During Period Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2021 tlcc Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2021 tlcc Class Of Warrant Or Right Cancelled During Period Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightCancelledDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights
500000 shares
CY2021 tlcc Class Of Warrant Or Right Canceled During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCanceledDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2021 tlcc Class Of Warrant Or Right Exercised During Period Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights
1034702 shares
CY2021 tlcc Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4500000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021 tlcc Class Of Warrant Or Right Exercised During Period Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights
1034702 shares
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 USD
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
35000 USD
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
35000 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 USD
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 USD
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7194412 shares
CY2021Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
1528384 shares
CY2021Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
30000 USD
CY2021Q4 tlcc Subscription Receivable Annual Interest Rate
SubscriptionReceivableAnnualInterestRate
0.05 pure
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
13000 USD
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
3135000 USD
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
38000 USD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
13000 USD
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
38000 USD
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
2841000 USD
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2953000 USD
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
957000 USD
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
96000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3798000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2857000 USD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3030000 USD
CY2021 tlcc Income Tax Reconciliation Interest Expense
IncomeTaxReconciliationInterestExpense
38000 USD
CY2020 tlcc Income Tax Reconciliation Interest Expense
IncomeTaxReconciliationInterestExpense
45000 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
82000 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
8000 USD
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-770000 USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-307000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3798000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2857000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
355000 USD
CY2021 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
0 USD
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
110000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
61352000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
61162000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
7949000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
81448000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1987000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
7063000 USD
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
5925000 USD
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
5796000 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3456000 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1642000 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2766000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
77650000 USD
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
352000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
81448000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
77650000 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3798000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2857000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 USD
CY2021Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
13111
CY2021Q4 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
918000 USD
CY2021 us-gaap Lease Cost
LeaseCost
874000 USD
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
325000 USD
CY2020 us-gaap Lease Cost
LeaseCost
1064000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1505000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1534000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1524000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1566000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1150000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
306000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7585000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1349000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6236000 USD
CY2021 us-gaap Sublease Income
SubleaseIncome
809000 USD
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1379000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0825 pure
CY2021 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1910000 USD
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2565000 USD

Files In Submission

Name View Source Status
0001753926-22-000353-index-headers.html Edgar Link pending
0001753926-22-000353-index.html Edgar Link pending
0001753926-22-000353.txt Edgar Link pending
0001753926-22-000353-xbrl.zip Edgar Link pending
ex211_2.htm Edgar Link pending
ex231_3.htm Edgar Link pending
ex311_4.htm Edgar Link pending
ex312_5.htm Edgar Link pending
ex321_6.htm Edgar Link pending
ex322_7.htm Edgar Link pending
ex42_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tlcc-20211231.htm Edgar Link pending
tlcc-20211231.xsd Edgar Link pending
tlcc-20211231_cal.xml Edgar Link unprocessable
tlcc-20211231_def.xml Edgar Link unprocessable
tlcc-20211231_htm.xml Edgar Link completed
tlcc-20211231_lab.xml Edgar Link unprocessable
tlcc-20211231_pre.xml Edgar Link unprocessable